Several strategies have been developed to distinguish BRCA-like from non-BRCA-like tumours, including detection of BRCA1 mutation, genomic scar assays or functional testing of HR capacity by measurement of RAD51 foci9,10. The gene discussed is RAD51; the disease is neoplasm.